 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||| rovaleucel (TT10) / Tessa Therap
Trial completion, Trial completion date, Trial primary completion date, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Oct 20, 2022
P3, N=330, Completed, Sponsor: Tessa Therapeutics
Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Feb 2022 | Trial primary completion date: Jan 2023 --> Feb 2022
- rovaleucel (TT10) / Tessa Therap
Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC) (7.2.E - Évry Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1488;
Thirteen out of 133 patients treated with EBV-CTL (9.8%) experienced EBV-CTL related AEs, all grade 1 and 2, except two grade 3 events of anemia and leukopenia that occurred in one patient. Conclusions EBV-CTL as first-line treatment in patients with R/M NPC had a favorable safety profile but did not demonstrate a longer OS vs standard of care (SOC) chemotherapy.
- |||| rovaleucel (TT10) / Tessa Therap
Trial primary completion date, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Mar 8, 2021
P3, N=330, Active, not recruiting, Sponsor: Tessa Therapeutics
Conclusions EBV-CTL as first-line treatment in patients with R/M NPC had a favorable safety profile but did not demonstrate a longer OS vs standard of care (SOC) chemotherapy. Trial primary completion date: Feb 2021 --> Jan 2023
- ||||| rovaleucel (TT10) / Tessa Therap
Enrollment closed, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Dec 13, 2019
P3, N=330, Active, not recruiting, Sponsor: Tessa Therapeutics
Trial primary completion date: Feb 2021 --> Jan 2023 Recruiting --> Active, not recruiting
- |||| rovaleucel (TT10) / Tessa Therap
Trial completion date, Trial primary completion date, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Mar 28, 2019
P3, N=330, Recruiting, Sponsor: Tessa Therapeutics
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||| rovaleucel (TT10) / Tessa Therap
Trial primary completion date, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Nov 27, 2017
P3, N=330, Recruiting, Sponsor: Tessa Therapeutics
Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| rovaleucel (TT10) / Tessa Therap
New P3 trial, Metastases: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - Oct 22, 2015
P3, N=330, Recruiting, Sponsor: Tessa Therapeutics